Kalaris Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $45.45M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | – | $-0.46 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 17, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | $-0.64 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | – | $-0.61 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | – | $-2.52 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 18, 2025 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 2, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 3, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 4, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Feb 15, 2023 | Before market open | – | – | – |
Press releases
Announcements Kalaris Therapeutics filed with the SEC
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
July 2026 Kalaris Company Overview
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
March 2026 Kalaris Company Overview
Regulation FD disclosure · EX-99.1 to Form 8-K
Oversubscribed $50.0 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Kalaris Therapeutics Reports Initial Positive Phase 1a Data for TH103 in Treatment-Naïve
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
statements, other than statements of historical fact, contained in this presentation, including statements regarding the strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management of
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Kalaris Reports Second Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
Kalaris Announces Closing of Merger with AlloVir
Acquisition or disposition completed · Results of operations · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
AlloVir, Inc. (AlloVir), a Delaware corporation and our predecessor company, consummated the previously announced merger (the Merger) pursuant to the terms of the Agreement and Plan of Merger, dated as of November 7,
Acquisition or disposition completed · Results of operations · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
AlloVir, Inc., a Delaware corporation and our predecessor company, consummated the previously announced merger (the Merger) pursuant to the terms of the Agreement and Plan of Merger, dated as of November 7, 2024 (the Merger
Acquisition or disposition completed · Results of operations · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K
Kalaris and AlloVir Announce Stockholder Approval of Merger
Executive or director change · Shareholder vote results · Other events · EX-99.2 to Form 8-K
AlloVir and Kalaris Therapeutics Announce Agreement for
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Company Overview November 2024 Exhibit
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel,
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
AlloVir Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
AlloVir Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
AlloVir Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
AlloVir Announces Pricing of Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
AlloVir Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AlloVir Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
AlloVir Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
AlloVir Announces $126.6 Million Registered Direct Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
AlloVir Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
AlloVir Appoints Shawn Tomasello to Its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
Results of operations · EX-99.1 to Form 8-K
Therapies J.P. Morgan Healthcare Conference January 10, 2022 CONFIDENTIAL & PROPRIETARY © 2022
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
AlloVir Announces Departure of Chief Medical Officer Agustin Melian
Regulation FD disclosure · EX-99.1 to Form 8-K
AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
AlloVir Virtual Investor Event December
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
T-Cell Therapies November 2021 CONFIDENTIAL & PROPRIETARY © 2021
Regulation FD disclosure · EX-99.1 to Form 8-K
AlloVir Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K